Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Authors:
Abstract
Background: The diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients may be difficult to establish because ABPA shares many characteristics with coexisting atopy or other lung infections in these patients. This study aimed to evaluate the sensitivity and specificity of various paraclinical parameters in the diagnosis of ABPA in patients with CF. Methods: Accumulated data from a 5‐year period in 238 CF patients were used to divide patients into two groups designated the ABPA group (n=26) and the non‐ABPA group (n=35). Patients in both groups were colonized with Aspergillus fumigatus, but only the ABPA group consistently demonstrated specific IgE antibodies and specific precipitins. Patients without A. fumigatus colonization were not assigned to either of these groups (n=177). By this selection as the true diagnosis, 10 patients were selected from the ABPA group and 10 patients from the non‐ABPA group. Results: The groups were comparable as to age, sex, lung function (P=0.6), and presence of chronic Pseudomonas aeruginosa infection (P>0.1). No significant difference between the groups in unspecific atopic parameters such as eosinophil count (P=0.9) or eosinophil cationic protein (ECP) in sputum, plasma, or serum (P=0.9, P=0.59, and P=0.9, respectively) was demonstrated. Total IgE was significantly higher in the ABPA group (P0.2). Statistically significantly higher levels in the ABPA group were demonstrated in specific IgE to Af. (PAf. (PAf. precipitins (PAf. tended to be higher (P=0.075) in the ABPA group. Specific IgE to Af. was determined by Magic Lite (ML), CAP, and Maxisorp (in‐house RAST). The CAP level was one to two classes higher than the ML level; however, the results were comparable (r=0.66, PAf. measured by CAP was the test which offered the highest positive predictive value (PPV) and negative predictive value (NPV). Optimal diagnostic cutoff levels for the diagnosis of ABPA were determined: class 2 for HR to Af., 200 kU/l for total IgE, and 3.5 (titer) for precipitating antibodies to Af., and class 2 for IgE to Af. (by CAP System). Conclusions: Unspecific atopy markers were of limited value for the diagnosis of ABPA. Patients with ABPA do not seem to be more atopic to other aeroallergens than non‐ABPA patients. The most valid parameters for the diagnosis of ABPA in CF are SPT to Af., IgE to Af. in combination with precipitating antibodies to Af., and/or total IgE.Keywords
This publication has 21 references indexed in Scilit:
- Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosisPediatric Pulmonology, 1999
- Development of Murine Monoclonal Antibodies for the Immunohistochemical Diagnosis of Systemic Bovine AspergillosisJournal of Veterinary Diagnostic Investigation, 1996
- Serum anti-Aspergillus fumigatus antibodies by immunoblot and ELISA in cystic fibrosis with allergic bronchopulmonary aspergillosisJournal of Allergy and Clinical Immunology, 1994
- Precise area determination of skin‐prick tests: validation of a scanning device and software for a personal computerClinical & Experimental Allergy, 1993
- Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assayJournal of Immunological Methods, 1991
- MaxisorpAllergy, 1989
- A new method for detecting histamine releaseInflammation Research, 1984
- Allergic bronchopulmonary aspergillosis in cystic fibrosisJournal of Allergy and Clinical Immunology, 1984
- Allergic bronchopulmonary aspergillosis complicating cystic fibrosis in childhood.Archives of Disease in Childhood, 1980
- Broncho-pulmonary Aspergillosis : A Review and a Report of Eight New CasesThorax, 1952